Acute Myeloid Leukemia (AML) is an aggressive cancer with poor overall survival due to frequent relapse. FMS-like tyrosine kinase (FLT3) is the most commonly mutated gene [...]

Identification of druggable mutations in Acute Myeloid Leukemia (AML), such as FLT3-ITD, has led to the development of targeted therapies capable of out-performing cytoto [...]

November 2013 issue of the Scribe. Contents include clinical trials for acute myeloid leukemia treatment, care for senior patients, liability insurance, management of use [...]

Acute myeloid leukemia (AML) is the most common leukemia in adults and is primarily diagnosed in older patients. The combination of the BCL2 inhibitor, venetoclax, with a [...]

Preponderant genomic sequencing and clinical evidence have revealed the remarkable heterogeneity that underpins leukemia. Such efforts have brought to the forefront new o [...]

Despite decades of conventional chemotherapy, the prognosis for patients with acute myeloid leukemia (AML) remains dismal, with 75% of patients succumbing to their diseas [...]

Gene transcription is fundamental in establishing and maintaining cell identity and function. All normal cells are encoded with the same DNA, so transcription is essentia [...]

This thesis is composed of two studies that utilizes different statistical methods to answer cancer research questions. The first study uses supervised and unsupervised s [...]